Rechallenge with Platinum plus Fluoropyrimidine +/– Epirubicin in Patients with Oesophagogastric Cancer

Publisher： Karger

E-ISSN： 1423-0232|79|1-2|150-158

ISSN： 0030-2414

Source： Oncology, Vol.79, Iss.1-2, 2010-12, pp. : 150-158

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate Cancer

By  

Oncology, Vol. 68, Iss. 1, 2005-04 ,pp. : 2-9

Karger

Access to resources Recommend Favorite

A Phase I Study of Paclitaxel and Epirubicin, without and with Filgrastim, for the Treatment of Platinum-Resistant Advanced Ovarian Cancer

By  

Oncology, Vol. 56, Iss. 4, 1999-05 ,pp. : 267-273

Karger

Access to resources Recommend Favorite

Phase I Study of High-Dose Epirubicin in Platinum-Pretreated Patients with Ovarian Carcinoma

By  

Oncology, Vol. 57, Iss. 1, 1999-07 ,pp. : 10-16

Karger

Access to resources Recommend Favorite

Final Results of ERASME-4: A Randomized Trial of First-Line Docetaxel plus either Capecitabine or Epirubicin for Metastatic Breast Cancer

By  

Oncology, Vol. 80, Iss. 3-4, 2011-07 ,pp. : 262-268

Karger

Access to resources Recommend Favorite

Docetaxel rechallenge after an initial good response in patients with metastatic castration‐resistant prostate cancer

By  

BJU INTERNATIONAL, Vol. 115, Iss. 5, 2015-05 ,pp. : 744-752

John Wiley & Sons Inc

Access to resources Recommend Favorite